Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology. The company develops CAR T-cells against both solid and liquid tumors based on its proprietary technology platform, iTANK, for a parallell activation of an innate immune response against cancer. Elicera also develops next generation oncolytic viruses with three combined mode-of-actions, applicable for treatment of most cancers.